Background: Pre-eclampsia is a multisystem progressive disorder which affects 4.6% of pregnancies worldwide. It is not an uncommon disease found in some women during pregnancy; however hyponatraemia secondary to pre-eclampsia presented antenally is rare with only few cases reported in the literature. Hyponatraemia in women with pre-eclampsia has significant implications on the maternal and fetal wellbeing causing decrease in maternal seizure threshold, fetal hyponatraemia, foetal jaundice, polyhydramnios and preterm labour. Therefore, a timely diagnosis and appropriate management is required.
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Case Report: We report a case of a 31-year-old Caucasian patient, G1P0 at 35+6 weeks of gestation, with type 1 diabetes, presented for her routine antenatal clinic with 1 week history of weakness, several episodes of hypoglycaemia and weight gain of 4 kg. On examination she had moderate bilateral pitting oedema, hyperreflexia and was normotensive with a blood pressure of 125/75 mmHg. Whilst on the ward the patient developed a hypertensive crisis of 182/91 mmHg followed by severe hyponatraemia of 122 mmol/L; the decision for induction of labour was made.
Results: Despite fluid restriction and tight control of her blood sugar level, the patient developed ketoacidosis and required immediate delivery via caesarean section. A 4kg male infant was delivered at 36+4 weeks gestation; with mild hyponatraemia of 130mmol/L, hypoglycaemia and neonatal jaundice which resolved spontaneously without much intervention.
Conclusions: We believe that this is the first case reported of a Type 1 diabetic patient presented with atypical pre-eclampsia complicated by hyponatraemia. Further literature review is underway and will be ready for presentation at PSANZ 2019. Background: All preterm infants with a PDA are exposed to unrestricted left-to-right shunt with increased pulmonary blood flow and cardiac volume load until closure occurs. Earlier closure can be achieved with non-steroidal anti-inflammatory drugs (NSAID) but without improving important clinical outcomes, hence the usefulness of NSAID treatment is questioned.
A DOUBLE BLIND, RANDOMISED CONTROLLED PILOT TRIAL OF EARLY PHARMACOLOGICAL TREATMENT VERSUS SUPPORTIVE MANAGEMENT IN PRETERM INFANTS WITH A PATENT DUCTUS ARTERIOSUS
Methods: Preterm infants <29 weeks gestation with a PDA >1.5 mm and <72 hours after birth were randomised to receive standard NSAID treatment versus supportive management alone (optimization of airway pressure, careful fluid management and diuretics as required). No open label NSAID treatment was allowed. The primary endpoints of this pilot trial were consent rate and incidence of open label treatment. Secondary clinical outcomes included PDA closure and chronic lung disease/death, the primary outcome for the full trial.
Results: 241 preterm infants <29 weeks were admitted during the study period. Of the 207 approached parents, 54% consented to the study. 47% of parents who declined this study did participate in other research studies. The average recruitment rate was 3.9 infants per month and 71 infants were randomised. One patient in each arm received open label treatment.
PDA closure rates were 74% (NSAID) versus 31% (supportive management) but this did not lead to lower CLD/death (60 versus 67%) or significant changes in other clinical outcomes.
Conclusion 
